NTLA vs PRME
NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis. PRME: A biotechnology company developing next-generation gene editing therapies based on its proprietary Prime Editing platform to cure serious genetic diseases.
Side-by-side fundamentals
| Metric | NTLA | PRME | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.13 | $3.09 | |
| Market cap as of 2026-07-23 | $1.6B | $564M | |
| Net margin as of 2026-07-23 | -597.0% | -4917.6% | NTLA higher |
| Operating margin as of 2026-07-23 | -636.6% | -5121.8% | NTLA higher |
| ROE as of 2026-07-23 | -57.3% | -188.8% | NTLA higher |
| ROA as of 2026-07-23 | -46.1% | -61.0% | NTLA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +45.0% | +4.9% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | +9.1% | n/a | |
| Beta as of 2026-07-23 | 1.78 | 2.27 | |
| 1-year return as of 2026-07-22 close | -17.5% | -31.7% | NTLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.